Song Xu-guang, Cao Jiang, Zeng Ling-yu, Zhang Huan-xin, Cheng Hai, Wang Man, Wang Li, Chen Chong, Xu Kai-lin
Department of Hematology, The Affiliated Hospital of Xuzhou Medical College, Xuzhou 221002, China.
Zhonghua Xue Ye Xue Za Zhi. 2013 Sep;34(9):757-61. doi: 10.3760/cma.j.issn.0253-2727.2013.09.005.
To establish a high efficient human coagulation factor VIII (FVIII) eukaryotic stable expression system using lentiviral vector, and determine its biosafety.
Lentiviral transfer plasmid carrying human B-domain-deleted FVIII(BDDhFVIII)-IRES-GFP(BDDhFVIII/pXZ9)or IRES-GFP(pXZ9) was constructed. Lentivirus particles were produced by transiently co-transfected 3-plasmids into 293FT cells and further concentrated via ultracentrifugation. CHO cells were infected, 72h later, the FVIII antigen (FVIII:Ag) concentration in the medium was examined by ELISA, the activity was detected via one stage coagulation,and the transcription of FVIII in the infected CHO cells was determined by RT-PCR.Virus infection ability in the medium and the gag gene in CHO cells were determined to evaluate the model's biosafety.
Lentiviral transfer plasmid BDDhFVIII-IRES-GFP(BDDhFVIII/pXZ9)carrying human B-domain-deleted FVIII or IRES-GFP (pXZ9) was successfully constructed, and high titer lentiviruses has been prepared. The lentivirus could infect CHO cells efficiently, after an additional 72 h, the FVIII:Ag concentration had up to (1724.9±283.7) mU/ml, the FVIII:C level increased to (10.58±1.55)%, and transcripts of BDDhFVIII mRNA could be measured by RT-PCR. Neither the gag gene nor the virus in the supernatant was detected.
Lentivirus-mediated human coagulation factor VIII could be expressed efficiently in CHO cells. The system couldn't produce offspring virus, proving a good biosafety.
利用慢病毒载体建立高效的人凝血因子VIII(FVIII)真核稳定表达系统,并确定其生物安全性。
构建携带人B结构域缺失FVIII(BDDhFVIII)-内部核糖体进入位点-绿色荧光蛋白(IRES-GFP)的慢病毒转移质粒(BDDhFVIII/pXZ9)或IRES-GFP(pXZ9)。通过将三质粒瞬时共转染至293FT细胞中产生慢病毒颗粒,并通过超速离心进一步浓缩。感染CHO细胞,72小时后,通过酶联免疫吸附测定法检测培养基中FVIII抗原(FVIII:Ag)浓度,通过一期凝血法检测活性,并通过逆转录聚合酶链反应(RT-PCR)测定感染的CHO细胞中FVIII的转录情况。测定培养基中的病毒感染能力以及CHO细胞中的gag基因,以评估该模型的生物安全性。
成功构建了携带人B结构域缺失FVIII的慢病毒转移质粒BDDhFVIII-IRES-GFP(BDDhFVIII/pXZ9)或IRES-GFP(pXZ9),并制备了高滴度的慢病毒。慢病毒能够高效感染CHO细胞,再过72小时后,FVIII:Ag浓度高达(1724.9±283.7)mU/ml,FVIII:C水平提高到(10.58±1.55)%,并且可通过RT-PCR检测到BDDhFVIII mRNA的转录本。未检测到gag基因和上清液中的病毒。
慢病毒介导的人凝血因子VIII能够在CHO细胞中高效表达。该系统不会产生子代病毒,证明具有良好的生物安全性。